Track AxoGen, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

AxoGen, Inc. AXGN · Stock Open AxoGen, Inc. in new tab

55.93 USD
EPS
-0.63
P/B
6.73
ROE
-10.35
Beta
1.15
Target Price
59.27 USD
AxoGen, Inc. logo

AxoGen, Inc.

🧾 Earnings Recap – Q3 2025

AxoGen delivered strong Q3 2025 results with revenue reaching $60.1 million, a 23.5% year-over-year growth, driven by robust demand across all nerve repair target markets.

  • Q3 sales increased to $60.1 million, with double-digit growth in extremities, oral maxillofacial, and breast markets.
  • High potential accounts contributed approximately 64% of revenue growth year-to-date, despite a transition phase affecting growth metrics.
  • Strong surgeon adoption of the AxoGen nerve care algorithm, particularly in mandible reconstruction and breast resensation procedures.
  • Successful completion of the hiring plan for commercial expansion, particularly in the breast resensation sales force.
  • Anticipation of BLA approval for Avance Nerve Graft in December 2025, expected to enhance market positioning.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 23, 2027
EPS-0.63
Book Value8.31
Price to Book6.73
Debt/Equity3.92
% Insiders2.394%
Growth
Revenue Growth0.26%
Earnings Growth3.00%
Estimates
Forward P/E79.28
Forward EPS0.71
Target Mean Price59.27

DCF valuation

Model fair value for AxoGen, Inc. (AXGN)
Result
Sign in to run the valuation for AXGN.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
11 analysts · consensus Strong buy · mean target 59.27 USD (low 56.00, high 65.00) · as of 15 Nov 2026
Low 56.00
Mean 59.27
High 65.00
Price 55.93
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

AxoGen, Inc. Logo AxoGen, Inc. Analysis (AXGN)

United States Health Care Official Website Stock

Is AxoGen, Inc. a good investment? AxoGen, Inc. (AXGN) is currently trading at 55.93 USD. Market analysts have a consensus price target of 59.27 USD. This suggests a potential upside from current levels.

Earnings Schedule: AxoGen, Inc. is expected to release its next earnings report on Feb. 23, 2027. The market consensus estimate for Forward EPS is 0.71.

Investor FAQ

Does AxoGen, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is AxoGen, Inc.?

AxoGen, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 23, 2027. The company currently has a trailing EPS of -0.63.

Company Profile

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.

Exchange Ticker
FRA (Germany) LT3.F
LSE (United Kingdom) 0HKD.L
NCM (Australia) AXGN
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2010
1.00 USD
Feb. 12, 2010 1.0000
▸2005
0.06 USD
Feb. 23, 2005 0.0600
▸1992
0.04 USD
July 10, 1992 0.0417
Stock Splits
Split Date Split Ratio to 1
July 10, 1992 1.05
July 12, 1993 1.05
July 11, 1994 1.05
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion